Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Sep;4(3):210-216.
doi: 10.5114/ceh.2018.78127. Epub 2018 Sep 10.

Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

Monika Pazgan-Simon  1 , Krzysztof A Simon  2 , Ewa Jarowicz  3 , Katarzyna Rotter  1 , Anna Szymanek-Pasternak  2 , Jolanta Zuwała-Jagiełło  4
Affiliations
Case Reports

Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

Monika Pazgan-Simon et al. Clin Exp Hepatol. 2018 Sep.

Abstract

Chronic hepatitis B virus (HBV) infection and HBV-related liver disease are estimated to affect about 240 million people worldwide. Now that a vaccine is available, the number of new HBV infection cases has plummeted. Yet, there are still regions with very high incidence of HBV. Hepatocellular carcinoma (HCC) is the fourth to six most common malignancy in men and the ninth most common malignancy in women worldwide. 54% of all HCC cases are HBV-associated, making it the most common cause of cancer worldwide. Hepatitis B therapy prevents progression of chronic hepatitis to cirrhosis and HCC development, but even with the best HBV treatment, such patients are still at risk of HCC. Also in patients after transarterial chemoembolization (TACE), liver resection (hepatectomy) or liver transplant, suppression of hepatitis B virus (HBV) improves patient survival. In this paper we present current possibilities of HCC and HBV treatment, which lead to improved survival and quality of life.

Keywords: HBV treatment; HCC; HCC treatment.

PubMed Disclaimer

References

    1. Sangiovanni A, Colombo M. Hepatocellular carcinoma – epidemiology. 2016. EASL Postgraduate course.
    1. Balogh J, Victor D, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016:341–353. - PMC - PubMed
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. - PubMed
    1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47–58. - PubMed
    1. European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185. - PubMed

Publication types